Descovy vs Genvoya
Side-by-side cost comparison based on Medicare Part D data
Descovy
Emtricitabine/TAF
Manufactured by Gilead
Genvoya
Elvitegravir/Cobicistat/Emtricitabine/TAF
Manufactured by Gilead
Descovy costs 33% less per claim than Genvoya ($2,418.00 vs $3,619.00). A generic version of Descovy is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Descovy | Genvoya |
|---|---|---|
| Avg Cost Per Claim | $2,418.00 | $3,619.00 |
| Total Medicare Spending | $1.6B | $2.3B |
| Total Beneficiaries | 86,000 | 54,000 |
| Total Claims | 648,000 | 648,000 |
| Annual Cost/Patient | $18,221.00 | $43,426.00 |
| Year-over-Year Change | +12.4% | -8.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Gilead | Gilead |
| Condition | HIV | HIV |
| Generic Name | Emtricitabine/TAF | Elvitegravir/Cobicistat/Emtricitabine/TAF |
Descovy vs Genvoya: What the Data Shows
Descovy (Emtricitabine/TAF) and Genvoya (Elvitegravir/Cobicistat/Emtricitabine/TAF) are both used to treat hiv. Based on Medicare Part D data, Descovy costs $2,418.00 per claim, which is 33% less than Genvoya at $3,619.00 per claim.
Medicare spent $1.6B on Descovy and $2.3B on Genvoya. In terms of patient reach, Descovy serves more beneficiaries (86,000 vs 54,000).
Year-over-year spending changed +12.4% for Descovy and -8.4% for Genvoya. Descovy saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Descovy is cheaper at $2,418.00 per claim, compared to $3,619.00 for Genvoya. That makes Descovy about 33% less expensive per claim based on Medicare Part D data.
Yes, both Descovy and Genvoya are used to treat hiv. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Emtricitabine/TAF and generic Elvitegravir/Cobicistat/Emtricitabine/TAF can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $1.6B on Descovy covering 86,000 beneficiaries, and $2.3B on Genvoya covering 54,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.